{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:42:03Z","timestamp":1791222123096,"version":"4.1.0"},"reference-count":111,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>\n                    Antimicrobial peptides (AMPs), long recognized for their broad-spectrum antimicrobial activity, have recently gained prominence as versatile anticancer agents. This review synthesizes recent advances positioning anticancer peptides (ACPs) at the forefront of novel oncological strategies, driven by their unique biophysical properties. Their cationic, amphipathic architecture enables selective electrostatic interactions with negatively charged malignant cell membranes, resulting in targeted, rapid membrane disruption and cell lysis. Beyond direct membrane effects, ACPs exert multifaceted intracellular actions including inhibition of DNA replication and protein synthesis, induction of mitochondrial dysfunction, and suppression of tumor angiogenesis. Increasingly, AMPs are recognized as potent immunomodulators capable of remodeling the tumor microenvironment. They induce immunogenic cell death, functioning as\n                    <jats:italic>in situ<\/jats:italic>\n                    vaccines that prime systemic antitumor immunity through intrinsic adjuvant effects that enhance antigen presentation. This review highlights clinically relevant AMPs categorized by Food and Drug Administration and European Medicines Agency approval status, illustrating the diversity of their therapeutic targets and mechanisms. We also critically examine key challenges hindering clinical translation, such as proteolytic instability, hemolytic toxicity, and suboptimal pharmacokinetics, and evaluate emerging solutions, including peptide engineering, nanoparticle-based delivery, and advanced conjugation strategies to improve stability, tumor specificity, and accumulation. Crucially, the integration of AMPs into combination regimens with conventional and immunotherapeutic agents presents a transformative strategy to overcome drug resistance and immune evasion. Nevertheless, clinical evidence remains limited, with most studies confined to early-phase trials. Ongoing efforts in optimizing peptide stability, developing targeted delivery systems, and identifying predictive biomarkers are essential to translate the promising preclinical profile of AMPs into clinically viable cancer therapeutics. With sustained interdisciplinary innovation and rigorous validation, AMPs are poised to become integral components of next-generation precision oncology.\n                  <\/jats:p>","DOI":"10.3389\/fmed.2026.1783547","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T05:33:42Z","timestamp":1774935222000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Advances in antimicrobial peptides: promising cancer treatments and vaccines"],"prefix":"10.3389","volume":"13","author":[{"given":"Gehane","family":"Ghaly","sequence":"first","affiliation":[{"name":"Department of Chemistry, The American University in Cairo","place":["New Cairo, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatem","family":"Tallima","sequence":"additional","affiliation":[{"name":"Department of Chemistry, The American University in Cairo","place":["New Cairo, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamer","family":"Shoeib","sequence":"additional","affiliation":[{"name":"Department of Chemistry, The American University in Cairo","place":["New Cairo, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"250","DOI":"10.20517\/2394-4722.2017.41","article-title":"Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead","volume":"3","author":"Oiseth","year":"2017","journal-title":"J Cancer Metastasis Treat"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"6276","DOI":"10.1021\/acs.jmedchem.9b00657","article-title":"Positive charge patterning and hydrophobicity of membrane-active antimicrobial peptides as determinants of activity, toxicity, and pharmacokinetic stability","volume":"62","author":"Stone","year":"2019","journal-title":"J Med Chem"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/aps.2010.162","article-title":"Enhancement of cytotoxicity of antimicrobial peptide Magainin II in tumor cells by Bombesin-targeted delivery","volume":"32","author":"Liu","year":"2011","journal-title":"Acta Pharmacol Sin"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2174\/138920306779025611","article-title":"Anticancer \u03b1-helical peptides and structure\/function relationships underpinning their interactions with tumour cell membranes","volume":"7","author":"Dennison","year":"2006","journal-title":"Curr Protein Pept Sci"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/978-981-13-3588-4_9","volume-title":"Antimicrobial Peptides: Basics for Clinical Application","author":"Hilchie","year":"2019"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"239","DOI":"10.4103\/jomfp.JOMFP_113_16","article-title":"Host defense peptides: an insight into the antimicrobial world","volume":"22","author":"Gupta","year":"2018","journal-title":"J Oral Maxillofac Pathol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.2174\/092986732709200327085156","article-title":"Antimicrobial peptides in host defense against drug-resistant bacterial and viral infections","volume":"27","author":"Di","year":"2020","journal-title":"Curr Med Chem"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3390\/polym4010539","article-title":"Antimicrobial peptides: multifunctional drugs for different applications","volume":"4","author":"Brandenburg","year":"2012","journal-title":"Polymers"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.drup.2011.02.001","article-title":"Fighting bacterial infections\u2014future treatment options","volume":"14","author":"Fernebro","year":"2011","journal-title":"Drug Resist Updat"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.3390\/molecules28031148","article-title":"Anti-cancer peptides: status and future prospects","volume":"28","author":"Ghaly","year":"2023","journal-title":"Molecules"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.2147\/IJN.S445333","article-title":"Anticancer mechanisms and potential anticancer applications of antimicrobial peptides and their nano agents","volume":"19","author":"Dong","year":"2024","journal-title":"Int J Nanomedicine"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"678","DOI":"10.3892\/ijo.2020.5099","article-title":"Anticancer peptide: physicochemical property, functional aspect and trend in clinical application","volume":"57","author":"Chiangjong","year":"2020","journal-title":"Int J Oncol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"6545","DOI":"10.1021\/bi0273563","article-title":"Mechanism of lipid bilayer disruption by the human antimicrobial peptide, LL-37","volume":"42","author":"Henzler Wildman","year":"2003","journal-title":"Biochemistry"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"7235","DOI":"10.1021\/bi9826299","article-title":"Mechanism of interaction of different classes of cationic antimicrobial peptides with planar bilayers and with the cytoplasmic membrane of Escherichia coli","volume":"38","author":"Wu","year":"1999","journal-title":"Biochemistry"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"12156","DOI":"10.1021\/ja062927q","article-title":"Antimicrobial peptides in action","volume":"128","author":"Leontiadou","year":"2006","journal-title":"J Am Chem Soc"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.yexcr.2012.12.017","article-title":"The elimination of P-glycoprotein over-expressing cancer cells by antimicrobial cationic peptide NK-2: the unique way of multi-drug resistance modulation","volume":"319","author":"Bankovi\u0107","year":"2013","journal-title":"Exp Cell Res"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1517\/13543784.15.8.933","article-title":"Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment","volume":"15","author":"Mader","year":"2006","journal-title":"Expert Opin Investig Drugs"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1111\/cbdd.13023","article-title":"Synthesis and biological evaluation of novel peptides based on antimicrobial peptides as potential agents with antitumor and multidrug resistance-reversing activities","volume":"90","author":"Zhang","year":"2017","journal-title":"Chem Biol Drug Des"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1006\/bbrc.1997.8014","article-title":"Expression of antimicrobial peptides has an antitumour effect in human cells","volume":"242","author":"Winder","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jcis.2016.05.002","article-title":"Membrane interactions of mesoporous silica nanoparticles as carriers of antimicrobial peptides","volume":"475","author":"Braun","year":"2016","journal-title":"J Colloid Interface Sci"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1158\/1535-7163.499.3.4","article-title":"Intravenous liposomal delivery of the snake venom disintegrin contortrostatin limits breast cancer progression","volume":"3","author":"Swenson","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.3892\/or.2012.1911","article-title":"Suppression of tumor invasion and migration in breast cancer cells following delivery of siRNA against Stat3 with the antimicrobial peptide PR39","volume":"28","author":"Tian","year":"2012","journal-title":"Oncol Rep"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-981-13-3588-4_7","volume-title":"Antimicrobial Peptides: Basics for Clinical Application","author":"Neundorf","year":"2019"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s00249-011-0682-7","article-title":"Antimicrobial peptides with cell-penetrating peptide properties and vice versa","volume":"40","author":"Splith","year":"2011","journal-title":"Eur Biophys J"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.biopha.2023.114996","article-title":"Current research status of anti-cancer peptides: mechanism of action, production, and clinical applications","author":"Chinnadurai","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"170","DOI":"10.18565\/aig.2024.180","article-title":"The use of Buserelin-depo in the treatment of combined pathology of reproductive organs","volume":"18","author":"Khashukoeva","year":"2024","journal-title":"Obstet Gynecol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"527","DOI":"10.3390\/cancers17030527","article-title":"Preclinical assessment of dactinomycin in KMT2A-rearranged infant acute lymphoblastic Leukemia","volume":"17","author":"Chiu","year":"2025","journal-title":"Cancer"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3390\/md23070283","article-title":"Marine-derived compounds: a new horizon in Cancer, renal, and metabolic disease therapeutics","volume":"23","author":"Zhang","year":"2025","journal-title":"Mar Drugs"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"668","DOI":"10.3390\/jpm11070668","article-title":"Plitidepsin: mechanisms and clinical profile of a promising antiviral agent against COVID-19","volume":"11","author":"Papapanou","year":"2021","journal-title":"J Pers Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2374647","DOI":"10.1080\/21645515.2024.2374647","article-title":"Efficacy and safety of tebentafusp in patients with metastatic uveal melanoma: a systematic review and meta-analysis","volume":"20","author":"Dian","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"pii: cancers13235968","DOI":"10.3390\/cancers13235968","article-title":"Gp-100 as a novel therapeutic target in uveal melanoma","volume":"13","author":"Martinez-Perez","year":"2021","journal-title":"Cancers (Basel)"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"32042","DOI":"10.1038\/s41598-025-16734-7","article-title":"Triptorelin associated adverse events evaluated using FAERS pharmacovigilance data","volume":"15","author":"Jia","year":"2025","journal-title":"Sci Rep"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"443","DOI":"10.32604\/or.2024.043948","article-title":"EMP2 promotes hepatocellular carcinoma proliferation and invasion by activating cellular autophagy","volume":"33","author":"Pang","year":"2025","journal-title":"Oncol Res"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"8069","DOI":"10.1021\/bi4005705","article-title":"Mechanism of glutathione transferase P1-1-catalyzed activation of the prodrug canfosfamide (TLK286, TELCYTA)","volume":"52","author":"Dourado","year":"2013","journal-title":"Biochemistry"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"5071","DOI":"10.3390\/ijerph19095071","article-title":"Complementary and alternative therapies in oncology","volume":"19","author":"Dawczak-D\u0119bicka","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s10753-011-9297-5","article-title":"Beneficial effect of a CXCR4 agonist in murine models of systemic inflammation","volume":"35","author":"Fan","year":"2012","journal-title":"Inflammation"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.21037\/tlcr-20-1241","article-title":"A narrative review of tumor-associated macrophages in lung cancer: regulation of macrophage polarization and therapeutic implications","volume":"10","author":"Sedighzadeh","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1007\/s40265-022-01795-z","article-title":"Darinaparsin: first approval","volume":"82","author":"Frampton","year":"2022","journal-title":"Drugs"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.3390\/ijms24032282","article-title":"Cytotoxic effects of Darinaparsin, a novel organic arsenical, against human Leukemia cells","volume":"24","author":"Yuan","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"5681","DOI":"10.3892\/ol.2019.10935","article-title":"Use of immunotherapy in the treatment of gastric cancer","volume":"18","author":"Yang","year":"2019","journal-title":"Oncol Lett"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/jmr.1017","article-title":"Binding of CDR-derived peptides is mechanistically different from that of high-affinity parental antibodies","volume":"23","author":"Timmerman","year":"2010","journal-title":"J Mol Recognit"},{"key":"ref42","first-page":"189","volume-title":"GI Hormones in Cancer","author":"Gilliam","year":"2004"},{"key":"ref43","volume-title":"Medical Microbiology","author":"Murphy","year":"1996"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.brainres.2013.07.002","article-title":"Endothelin B receptor agonist, IRL-1620, enhances angiogenesis and neurogenesis following cerebral ischemia in rats","volume":"1528","author":"Leonard","year":"2013","journal-title":"Brain Res"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.mib.2004.08.013","article-title":"Taking inventory: antibacterial agents currently at or beyond phase 1","volume":"7","author":"Bush","year":"2004","journal-title":"Curr Opin Microbiol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.micpath.2024.106931","article-title":"Novel antimicrobial peptides based on Protegrin-1: in silico and in vitro assessments","author":"Goki","year":"2024","journal-title":"Microb Pathog"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.2174\/1570159X20999220131163504","article-title":"Transient opening of the blood-brain barrier by vasoactive peptides to increase CNS drug delivery: reality versus wishful thinking?(P3-12.003)","volume":"98","author":"Smith-Cohn","year":"2022","journal-title":"Neurology"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1158\/1940-6207.CAPR-22-0388","article-title":"Phase II trial of nelipepimut-S peptide vaccine in women with ductal carcinoma in situ","volume":"16","author":"O'Shea","year":"2023","journal-title":"Cancer Prev Res"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"6628","DOI":"10.1016\/j.bmc.2011.06.050","article-title":"In vitro and in vivo evaluation of select kahalalide F analogs with antitumor and antifungal activities","volume":"19","author":"Shilabin","year":"2011","journal-title":"Bioorg Med Chem"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"450","DOI":"10.20959\/wjpps20215-18852","article-title":"A voyage from the sea to clinical studies for innovative anticancer therapeutics derived from marine origins","volume":"10","author":"Tidke","year":"2021","journal-title":"World J Pharm Pharm Sci"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.tips.2010.02.005","article-title":"The odyssey of marine pharmaceuticals: a current pipeline perspective","volume":"31","author":"Mayer","year":"2010","journal-title":"Trends Pharmacol Sci"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"e304","DOI":"10.1097\/MPH.0000000000002054","article-title":"Augmented antitumor activity for novel dual PI3K\/BDR4 inhibitors, SF2523 and SF1126 in Ewing sarcoma","volume":"43","author":"Goldin","year":"2021","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3390\/ph18010036","article-title":"GnRH peptide antagonist: comparative analysis of chemistry and formulation with implications for clinical safety and efficacy","volume":"18","author":"Patel","year":"2024","journal-title":"Pharmaceuticals"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"5204","DOI":"10.1038\/s41598-025-89882-5","article-title":"Inhibiting CXCR4 reduces immunosuppressive effects of myeloid cells in breast cancer immunotherapy","volume":"15","author":"Ciavattone","year":"2025","journal-title":"Sci Rep"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3109\/10717544.2014.905651","article-title":"Bleomycin A6-loaded anionic liposomes with in situ gel as a new antitumoral drug delivery system","volume":"23","author":"Ding","year":"2016","journal-title":"Drug Deliv"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13062-024-00590-y","article-title":"Boanmycin overcomes bortezomib resistance by inducing DNA damage and endoplasmic reticulum functional impairment in multiple myeloma","volume":"20","author":"Wang","year":"2025","journal-title":"Biol Direct"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"356","DOI":"10.22377\/ajp.v14i03.3685","article-title":"Apoptotic effect of bleomycin formulated in cinnamon oil nanoemulsion on HeLa cervical cancer cells","volume":"14","author":"Alkhatib","year":"2020","journal-title":"Asian J Pharm"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/978-94-009-0835-2_2","volume-title":"The Comparative Physiology of Regulatory Peptides","author":"Vigna","year":"1989"},{"key":"ref59","first-page":"927","article-title":"Bombesin-drug conjugates in targeted therapy for small cell lung cancer","volume":"12","author":"Zhang","year":"2022","journal-title":"Am J Cancer Res"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3390\/md19070363","article-title":"Marine antitumor peptide dolastatin 10: biological activity, structural modification and synthetic chemistry","volume":"19","author":"Gao","year":"2021","journal-title":"Mar Drugs"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1021\/acs.jnatprod.1c01135","article-title":"Discovery and development of dolastatin 10-derived antibody drug conjugate anticancer drugs","volume":"85","author":"Singh","year":"2022","journal-title":"J Nat Prod"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"579","DOI":"10.13005\/bpj\/2398","article-title":"Marine antineoplastic templates: clinical trials (I\u2013III) and motifs carried via antibodies to target specific cancerous tissues","volume":"15","author":"El-Shorbagi","year":"2022","journal-title":"Biomed Pharmacol J"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"1332922","DOI":"10.3389\/fimmu.2024.1332922","article-title":"LTX-315 triggers anticancer immunity by inducing MyD88-dependent maturation of dendritic cells","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1002\/pros.21169","article-title":"Ozarelix, a fourth generation GnRH antagonist, induces apoptosis in hormone refractory androgen receptor negative prostate cancer cells modulating expression and activity of death receptors","volume":"70","author":"Festuccia","year":"2010","journal-title":"Prostate"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ejphar.2018.03.032","article-title":"Usefulness of pharmacokinetic\/efficacy analysis of an investigational kisspeptin analog, TAK-448, in quantitatively evaluating anti-tumor growth effect in the rat VCaP androgen-sensitive prostate cancer model","volume":"828","author":"Ishikawa","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/COC.0000000000001014","article-title":"A phase I trial of the ABCB1 inhibitor, oral valspodar, in combination with paclitaxel in patients with advanced solid tumors","volume":"46","author":"Fracasso","year":"2023","journal-title":"Am J Clin Oncol"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"104032","DOI":"10.1016\/j.critrevonc.2023.104032","article-title":"Application of VEGF\/VEGFR peptide vaccines in cancer: a systematic review of clinical trials","volume":"187","author":"Zahedipour","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3390\/cells10020292","article-title":"The role of gonadotropin-releasing hormone (GnRH) in endometrial cancer","volume":"10","author":"Emons","year":"2021","journal-title":"Cells"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/nri.2016.125","article-title":"Human immune system variation","volume":"17","author":"Brodin","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nri.2016.29","article-title":"The immunology of host defence peptides: beyond antimicrobial activity","volume":"16","author":"Hancock","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1126\/science.286.5439.525","article-title":"\u03b2-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6","volume":"286","author":"Yang","year":"1999","journal-title":"Science"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.4049\/jimmunol.172.2.1146","article-title":"The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization","volume":"172","author":"Davidson","year":"2004","journal-title":"J Immunol"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"R14","DOI":"10.1016\/j.cub.2015.11.017","article-title":"Antimicrobial peptides","volume":"26","author":"Zhang","year":"2016","journal-title":"Curr Biol"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/s41573-019-0058-8","article-title":"Antimicrobial host defence peptides: functions and clinical potential","volume":"19","author":"Mookherjee","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"ref75","first-page":"227","article-title":"AMPs and innate immunity in head and neck cancer\u2014a defensive role and therapeutic opportunity","volume":"22","author":"Pahl","year":"2016","journal-title":"Oral Dis"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"28565","DOI":"10.1074\/jbc.M606031200","article-title":"A synergism between temporin L and temporin B in killing gram-negative bacteria","volume":"281","author":"Rosenfeld","year":"2006","journal-title":"J Biol Chem"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1378\/chest.15-1353","article-title":"Antimicrobial peptides and innate lung defenses: role in infectious and noninfectious lung diseases and therapeutic applications","volume":"149","author":"Hiemstra","year":"2016","journal-title":"Chest"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.bbamcr.2014.11.006","article-title":"Apoptotic human neutrophil peptide-1 anti-tumor activity revealed by cellular biomechanics","volume":"1853","author":"Gaspar","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"348","DOI":"10.15698\/cst2019.11.204","article-title":"LTX-315 sequentially promotes lymphocyte-independent and lymphocyte-dependent antitumor effects","volume":"3","author":"Liao","year":"2019","journal-title":"Cell Stress"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/intimm\/dxw015","article-title":"Vaccine adjuvants as potential cancer immunotherapeutics","volume":"28","author":"Temizoz","year":"2016","journal-title":"Int Immunol"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1039\/c5sc03892h","article-title":"Peptide-based synthetic vaccines","volume":"7","author":"Skwarczynski","year":"2016","journal-title":"Chem Sci"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nrd3591","article-title":"Designing antimicrobial peptides: form follows function","volume":"11","author":"Fjell","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.coph.2006.04.006","article-title":"Antibacterial peptides for therapeutic use: obstacles and realistic outlook","volume":"6","author":"Marr","year":"2006","journal-title":"Curr Opin Pharmacol"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"116709","DOI":"10.1016\/j.biopha.2024.116709","article-title":"The role and future prospects of artificial intelligence algorithms in peptide drug development","volume":"175","author":"Chen","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1038\/srep02984","article-title":"In silico models for designing and discovering novel anticancer peptides","volume":"3","author":"Tyagi","year":"2013","journal-title":"Sci Rep"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"bbaa153","DOI":"10.1093\/bib\/bbaa153","article-title":"AntiCP 2.0: an updated model for predicting anticancer peptides","volume":"22","author":"Agrawal","year":"2021","journal-title":"Brief Bioinform"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.3390\/molecules24101973","article-title":"ACPred: a computational tool for the prediction and analysis of anticancer peptides","volume":"24","author":"Schaduangrat","year":"2019","journal-title":"Molecules"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"13398","DOI":"10.1038\/s41598-023-40160-2","article-title":"Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management","volume":"13","author":"Agu","year":"2023","journal-title":"Sci Rep"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"732","DOI":"10.36468\/pharmaceutical-sciences.824","article-title":"In vivo antinociceptive effect of methanolic extract of Ipomoea marginata Desr. In rodents as well as in silico molecular docking of some phytoconstituents from the plant","volume":"83","author":"Potluri","year":"2021","journal-title":"Indian J Pharm Sci"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"486","DOI":"10.4103\/0250-474x.73905","article-title":"Molecular docking studies with rabies virus glycoprotein to design viral therapeutics","volume":"72","author":"Tomar","year":"2010","journal-title":"Indian J Pharm Sci"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1039\/d5cc04998a","article-title":"Peptide-based drug design using generative AI","volume":"62","author":"Ekambaram","year":"2026","journal-title":"Chem Commun"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12602-025-10856-0","article-title":"AI-driven discovery and design of antimicrobial peptides: progress, challenges, and opportunities","volume":"22","author":"Meng","year":"2025","journal-title":"Probiotics Antimicrob Proteins"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1038\/s41467-018-04434-y","article-title":"X-ray structure of a carpet-like antimicrobial defensin\u2013phospholipid membrane disruption complex","volume":"9","author":"J\u00e4rv\u00e5","year":"2018","journal-title":"Nat Commun"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.semcdb.2018.02.023","article-title":"Multifaceted immune functions of human defensins and underlying mechanisms","volume":"88","author":"Fruitwala","year":"2019","journal-title":"Semin Cell Dev Biol"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.2174\/1871520619666191011161314","article-title":"Sera\/organ lysates of selected animals living in polluted environments exhibit cytotoxicity against cancer cell lines","volume":"19","author":"Jeyamogan","year":"2019","journal-title":"Anti-Cancer Agents Med Chem Anti-Cancer Agents"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"5330","DOI":"10.1046\/j.1432-1327.2000.01536.x","article-title":"The antibiotic and anticancer active aurein peptides from the Australian bell frogs Litoria aurea and Litoria raniformis: the solution structure of aurein 1.2","volume":"267","author":"Rozek","year":"2000","journal-title":"Eur J Biochem"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/S0006-3495(91)82126-9","article-title":"Orientation of melittin in phospholipid bilayers. A polarized attenuated total reflection infrared study","volume":"60","author":"Frey","year":"1991","journal-title":"Biophys J"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1046\/j.1432-1033.2003.03462.x","article-title":"nNOS inhibition, antimicrobial and anticancer activity of the amphibian skin peptide, citropin 1.1 and synthetic modifications: the solution structure of a modified citropin 1.1","volume":"270","author":"Doyle","year":"2003","journal-title":"Eur J Biochem"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3390\/polym10050489","article-title":"A novel delivery system for the controlled release~ of antimicrobial peptides: citropin 1.1 and temporin A","volume":"10","author":"Piotrowska","year":"2018","journal-title":"Polymers"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"4886","DOI":"10.1021\/jm050996u","article-title":"Structural determinants for the membrane interaction of novel bioactive undecapeptides derived from gaegurin 5","volume":"49","author":"Won","year":"2006","journal-title":"J Med Chem"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1016\/j.bbamem.2008.10.021","article-title":"Action mechanism and structural requirements of the antimicrobial peptides, gaegurins","volume":"1788","author":"Won","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/jb\/mvh114","article-title":"Induction of transient ion channel-like pores in a cancer cell by antibiotic peptide","volume":"136","author":"Ye","year":"2004","journal-title":"J Biochem"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1471-2490-8-5","article-title":"Antimicrobial peptides of the cecropin-family show potent antitumor activity against bladder cancer cells","volume":"8","author":"Suttmann","year":"2008","journal-title":"BMC Urol"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/cbdd.13381","article-title":"The activity and action mechanism of novel short selective LL-37-derived anticancer peptides against clinical isolates of Escherichia coli","volume":"93","author":"Aghazadeh","year":"2019","journal-title":"Chem Biol Drug Des"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"107237","DOI":"10.1016\/j.bej.2019.107237","article-title":"Utilization of antimicrobial peptides, analogues and mimics in creating antimicrobial surfaces and bio-materials","volume":"150","author":"Pinto","year":"2019","journal-title":"Biochem Eng J"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10989-014-9435-7","article-title":"ACPP: a web server for prediction and design of anti-cancer peptides","volume":"21","author":"Vijayakumar","year":"2015","journal-title":"Int J Pept Res Ther"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"16895","DOI":"10.18632\/oncotarget.7815","article-title":"iACP: a sequence-based tool for identifying anticancer peptides","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1093\/bioinformatics\/bty451","article-title":"ACPred-FL: a sequence-based predictor using effective feature representation to improve the prediction of anti-cancer peptides","volume":"34","author":"Wei","year":"2018","journal-title":"Bioinformatics"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1093\/bib\/bbz088","article-title":"ACPred-fuse: fusing multi-view information improves the prediction of anticancer peptides","volume":"21","author":"Rao","year":"2020","journal-title":"Brief Bioinform"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1783547\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T05:33:44Z","timestamp":1774935224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1783547\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":111,"alternative-id":["10.3389\/fmed.2026.1783547"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1783547","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"article-number":"1783547"}}